MedTrace Logo

Safety Study of NHL With 90Y-hLL2 IgG

NCT00421395 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2021-08-16

No results posted yet for this study

Summary

This will be an open label, multiple center, non-randomized, dose-escalation Phase I/II trial, designed to evaluate the safety and effectiveness of a repeated, outpatient regimen utilizing IMMU-hLL2 intact monoclonal antibody IgG labeled with different doses of 90Y for the treatment of patients B-cell lymphoma (NHL).

Conditions

  • NHL
  • B-cell NHL
  • Non-Hodgkins Lymphoma

Interventions

BIOLOGICAL

90Y-hLL2

weekly dosing for either 2 or 3 weeks

Sponsors & Collaborators

Principal Investigators

  • William A Wegener, MD, PhD · Gilead Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00421395 on ClinicalTrials.gov